secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001802768-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q1 Portfolio Receipts +10% to $925M; raises FY 2026 guidance
---------------------------------------------------------------------------

- Royalty Receipts grew 13% to $887M; driven by Tremfya (+79%), Voranigo (+140%), Evrysdi (+51%).
- Adjusted EBITDA non-GAAP $889M (+21% YoY); Portfolio Cash Flow $722M (+18%).
- Full-year 2026 Portfolio Receipts guidance raised to $3,325M-$3,450M (prev. $3,275M-$3,425M).
- Announced up to $1.25B in royalty transactions; $528M capital deployed in Q1.
- Recorded $69M non-cash impairment on Tazverik; positive Phase 3 data for daraxonrasib and Myqorzo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/0001802768-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001802768-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer